Cerebral Blood Flow & Autoregulation

Quick Answer

Cerebral blood flow (CBF) averages 50 mL/100g/min (750 mL/min total), representing 15% of cardiac output to an organ comprising only 2% of body weight. Grey matter receives 80-100 mL/100g/min while white matter receives 20-25 mL/100g/min due to differing metabolic demands. CBF is tightly coupled to cerebral metabolism (CMRO2 3.5 mL O2/100g/min) through flow-metabolism coupling.

Cerebral autoregulation maintains constant CBF across a range of mean arterial pressures, classically described as 50-150 mmHg (Lassen 1959), though more recent evidence suggests a narrower plateau of 60-90 mmHg. Autoregulation involves myogenic (Bayliss effect), metabolic (CO2, adenosine), and neurogenic mechanisms. The CO2 reactivity of cerebral vessels is powerful: CBF changes 3-4% per mmHg PaCO2 change (range 20-80 mmHg).

Cerebral perfusion pressure (CPP) = MAP - ICP (or MAP - CVP if CVP exceeds ICP). Brain Trauma Foundation guidelines recommend CPP 60-70 mmHg in severe TBI. The Monro-Kellie doctrine states that the sum of brain (80%), blood (10%), and CSF (10%) volumes is constant within the rigid cranium; increase in one component necessitates decrease in others.

Impaired autoregulation occurs in TBI, stroke, severe sepsis, and subarachnoid haemorrhage, making the brain vulnerable to blood pressure fluctuations. Temperature affects CBF by 6-7% per degree Celsius change in brain temperature.

---

CICM Exam Focus

Written Exam High-Yield Topics

1. Normal CBF values: 50 mL/100g/min total; grey matter 80-100, white matter 20-25 mL/100g/min
2. Autoregulation curve: Classical 50-150 mmHg (Lassen); modern evidence suggests 60-90 mmHg
3. Autoregulation mechanisms: Myogenic (Bayliss effect), metabolic (CO2, H+, adenosine, K+), neurogenic
4. CO2 reactivity: 3-4% change per mmHg PaCO2; mechanism and clinical application
5. O2 reactivity: Minimal until PaO2 less than 50 mmHg, then significant vasodilation
6. Monro-Kellie doctrine: Brain 80%, blood 10%, CSF 10%; compliance and elastance concepts
7. CPP calculation: CPP = MAP - ICP; targets 60-70 mmHg in TBI
8. ICP waveforms: Normal P1 greater than P2 greater than P3; pathological P2 greater than P1
9. Lundberg waves: A waves (plateau, 50-100 mmHg), B waves (0.5-2/min), C waves (4-8/min)
10. Blood-brain barrier: Tight junctions, endothelial cells, astrocytic endfeet; breakdown in injury
11. Temperature effects: 6-7% CBF decrease per degree Celsius reduction
12. Pharmacological effects: Propofol/barbiturates decrease CMRO2 and CBF; ketamine effects
13. Flow-metabolism coupling: CBF increases with CMRO2; disrupted in pathology

Viva Voce Themes

• Draw and explain the cerebral autoregulation curve
• Describe the mechanisms of cerebral autoregulation
• Explain the relationship between PaCO2 and cerebral blood flow
• Discuss the Monro-Kellie doctrine and ICP dynamics
• Outline the blood-brain barrier structure and function
• Compare the effects of sedative agents on cerebral physiology
• Apply CPP management principles to a TBI patient
• Explain flow-metabolism coupling and its clinical significance

Common SAQ Stems

• "Describe the factors that influence cerebral blood flow" (10-15 marks)
• "Outline the mechanisms of cerebral autoregulation" (8-10 marks)
• "Explain the relationship between carbon dioxide and cerebral blood flow" (8-10 marks)
• "Describe the Monro-Kellie doctrine and its clinical implications" (10-12 marks)
• "Discuss the physiological effects of hyperventilation on the brain" (10 marks)

---

Key Points

1. Normal CBF is 50 mL/100g/min (750 mL/min total), representing 15% of cardiac output to 2% of body mass

2. Grey matter CBF (80-100 mL/100g/min) is 4-5 times higher than white matter CBF (20-25 mL/100g/min) due to higher metabolic activity

3. Cerebral autoregulation maintains constant CBF between MAP 50-150 mmHg (classical view) or 60-90 mmHg (modern evidence) through myogenic, metabolic, and neurogenic mechanisms

4. CO2 reactivity causes 3-4% change in CBF per mmHg change in PaCO2 (range 20-80 mmHg); hyperventilation reduces CBF and ICP but risks ischaemia

5. Hypoxic vasodilation occurs only below PaO2 50 mmHg (6.7 kPa); above this threshold, PaO2 has minimal effect on CBF

6. Cerebral perfusion pressure (CPP = MAP - ICP) should be maintained at 60-70 mmHg in TBI; values less than 50 mmHg cause ischaemia

7. Monro-Kellie doctrine: Fixed intracranial volume (brain 80%, blood 10%, CSF 10%); increase in one component requires compensatory decrease in others

8. Impaired autoregulation occurs in TBI, SAH, stroke, severe sepsis, making CBF pressure-passive and vulnerable to MAP changes

9. Temperature affects CBF by approximately 6-7% per degree Celsius; hypothermia reduces both CMRO2 and CBF

10. Blood-brain barrier maintains ionic homeostasis through tight junctions; breakdown in injury allows vasogenic oedema and drug penetration

---

Normal Cerebral Blood Flow

Global Cerebral Blood Flow

Cerebral blood flow is remarkably high relative to brain mass, reflecting the extraordinary metabolic demands of neuronal activity. The brain receives approximately 15% of cardiac output (750 mL/min) despite comprising only 2% of body weight. This is delivered via four arteries: two internal carotid arteries (70% of total flow) and two vertebral arteries (30% of total flow) that unite to form the Circle of Willis, providing collateral circulation (PMID: 13645234).

Normal CBF values:

The difference between grey and white matter flow (4:1 ratio) reflects their differing metabolic demands. Grey matter contains neuronal cell bodies with high synaptic activity and oxygen consumption, while white matter consists primarily of myelinated axons with lower metabolic requirements (PMID: 9727638).

Measurement of Cerebral Blood Flow

Kety-Schmidt Method (1948)

Seymour Kety and Carl Schmidt developed the first quantitative method for measuring CBF in humans using the Fick principle applied to an inert, diffusible tracer (nitrous oxide). Their landmark 1948 paper established normal CBF at 54 mL/100g/min and CMRO2 at 3.5 mL O2/100g/min (PMID: 16695568).

The method requires:

• Arterial and jugular venous blood sampling
• Inhalation of 15% N2O for 10-15 minutes
• Application of the Fick equation: CBF = (amount of N2O taken up by brain) / (arteriovenous N2O difference)

Modern CBF measurement techniques:

Transcranial Doppler (TCD) is the most commonly used bedside technique in intensive care. Flow velocity (not flow) is measured in the middle cerebral artery through the temporal window. Normal MCA mean velocity is 55-80 cm/sec. Velocity changes correlate with flow changes if vessel diameter remains constant, which is valid within the autoregulatory range but may not hold during extremes of CO2 or blood pressure (PMID: 2010644).

Regional Cerebral Blood Flow

CBF varies substantially across brain regions, reflecting regional metabolic activity. Flow-metabolism coupling ensures that active regions receive proportionally higher blood flow.

Regional variations:

• Sensorimotor cortex: Increases during motor activity (activation hyperaemia)
• Visual cortex: Increases during visual stimulation
• Prefrontal cortex: Higher during cognitive tasks
• Basal ganglia: Moderate resting flow with activity-dependent increases
• White matter: Low but essential flow; susceptible to watershed ischaemia
• Hippocampus: Moderate flow; highly sensitive to ischaemia

Functional hyperaemia (neurovascular coupling) describes the regional increase in CBF that accompanies increased neuronal activity. This is mediated by:

1. Neuronal signalling: Glutamate release activates astrocytic calcium signalling
2. Astrocytic mediators: Release of K+, prostaglandins, EETs (epoxyeicosatrienoic acids)
3. Vascular response: Arteriolar and capillary pericyte dilation
4. Nitric oxide: Neuronal and endothelial NOS activation

The coupling of flow to metabolism is disrupted in many pathological states including TBI, stroke, and sepsis, contributing to secondary brain injury (PMID: 17991892).

---

Cerebral Metabolism

Cerebral Metabolic Rate of Oxygen (CMRO2)

The brain has an extraordinarily high metabolic rate despite its small mass. CMRO2 is 3.5 mL O2/100g/min (approximately 50 mL/min total), representing 20% of whole-body oxygen consumption in an organ comprising only 2% of body mass (PMID: 16695568).

Key metabolic parameters:

Oxygen extraction:

The brain extracts approximately 30-35% of delivered oxygen, giving a normal arteriovenous oxygen difference (AVDO2) of 6-7 mL O2/100mL blood. This is lower than myocardium (70%) but higher than most other organs, reflecting the brain's high metabolic rate but also its substantial metabolic reserve.

Jugular venous oxygen saturation (SjvO2) is normally 55-75%. Values below 50% suggest cerebral hypoxia/ischaemia (extraction exceeding supply), while values above 75% suggest hyperaemia or reduced metabolism (PMID: 8629618).

Glucose Utilisation

The brain is almost exclusively dependent on glucose as its metabolic substrate under normal conditions. CMRglucose is 5.5 mg/100g/min (approximately 120g/day), representing 25% of total body glucose utilisation.

Glucose metabolism:

• Aerobic glycolysis: 1 glucose yields 36-38 ATP (dominant pathway)
• Anaerobic glycolysis: 1 glucose yields 2 ATP (rapidly depletes reserves)
• Glycogen stores: Less than 1 micromol/g brain (depleted within 2-3 minutes of ischaemia)
• Ketone bodies: Can provide up to 60% of energy during prolonged fasting

The brain lacks significant glycogen reserves, making it exquisitely vulnerable to interruption of glucose and oxygen supply. Complete cessation of blood flow leads to ATP depletion within 4-5 minutes and irreversible neuronal damage within 5-10 minutes (PMID: 10323240).

Oxygen-glucose index (OGI):

OGI = 6 x CMRO2 / CMRglucose

Normal OGI is approximately 6, reflecting complete oxidation of glucose. Lower values indicate anaerobic metabolism or non-oxidative glucose consumption. OGI decreases during hypoxia, ischaemia, and seizures (PMID: 7667896).

Flow-Metabolism Coupling

Under normal conditions, CBF is tightly coupled to CMRO2, ensuring adequate oxygen delivery to match metabolic demand. This coupling ratio (CBF/CMRO2) is normally 20:1.

Coupling mechanisms:

1. Metabolic hypothesis: Increased metabolism produces vasodilatory metabolites (H+, K+, adenosine, CO2)
2. Neuronal signalling: Direct neural control of vascular tone via perivascular nerves
3. Astrocytic mediation: Astrocytes sense neuronal activity and signal to vessels via calcium waves
4. Nitric oxide: Neuronal NOS (nNOS) produces NO during neuronal activity
5. Prostaglandins: COX-derived prostanoids dilate cerebral vessels

Clinical relevance:

Flow-metabolism coupling is preserved with most sedative agents that reduce CMRO2 (propofol, barbiturates, benzodiazepines), resulting in parallel reductions in CBF. This is the physiological basis for metabolic suppression therapy in refractory intracranial hypertension.

Coupling is disrupted in:

• Traumatic brain injury
• Subarachnoid haemorrhage
• Ischaemic stroke
• Severe sepsis
• Cardiopulmonary bypass
• Extreme hypothermia

Loss of coupling means that metabolic demand may exceed supply (luxury perfusion or relative ischaemia), contributing to secondary brain injury (PMID: 19204212).

---

Cerebral Autoregulation

Definition and Historical Context

Cerebral autoregulation is the intrinsic ability of cerebral blood vessels to maintain relatively constant CBF despite changes in cerebral perfusion pressure (CPP) or mean arterial pressure (MAP).

Lassen's Classic Autoregulation Curve (1959)

Niels Lassen compiled data from 11 studies in 376 subjects to create the iconic autoregulation curve, published in Physiological Reviews in 1959. This landmark paper established the concept of a "plateau" region where CBF remains constant between MAP 50-150 mmHg (PMID: 13645234).

Key features of Lassen's curve:

• Lower limit of autoregulation (LLA): MAP approximately 50 mmHg
• Upper limit of autoregulation (ULA): MAP approximately 150 mmHg
• Plateau region: CBF constant at approximately 50 mL/100g/min
• Below LLA: CBF falls linearly with pressure (ischaemia risk)
• Above ULA: CBF rises with pressure (breakthrough hyperaemia, oedema)

Modern Understanding

More recent evidence has challenged the traditional view of the autoregulation curve, suggesting that the plateau is narrower than classically taught (PMID: 34197581).

Brassard and colleagues (2021) re-analysed Lassen's original data and found that:

1. The original curve was constructed from between-subject data, not within-subject responses
2. The true autoregulatory range may be only 60-90 mmHg in healthy individuals
3. The curve is more pressure-passive than previously believed
4. There is substantial inter-individual variability

Contemporary autoregulation parameters:

This has important clinical implications: even modest hypotension (MAP 60-70 mmHg) may exceed the lower limit in some patients, particularly those with chronic hypertension (rightward-shifted curve) (PMID: 34197581).

Mechanisms of Autoregulation

Autoregulation involves three primary mechanisms that act in concert to maintain constant CBF:

1. Myogenic Mechanism (Bayliss Effect)

The myogenic response is the intrinsic ability of vascular smooth muscle to contract in response to stretch (increased transmural pressure) and relax in response to reduced stretch.

Mechanism:

• Increased intravascular pressure stretches smooth muscle cells
• Stretch-activated cation channels open (TRP channels)
• Membrane depolarisation opens voltage-gated Ca2+ channels
• Calcium influx causes smooth muscle contraction
• Vasoconstriction increases resistance, reducing flow
• Response time: 5-10 seconds

The Bayliss effect is the dominant mechanism for rapid autoregulatory responses and operates primarily in arterioles 50-150 micrometres in diameter (PMID: 14654596).

2. Metabolic Mechanism

Metabolic factors link tissue oxygen/substrate requirements to vascular tone, ensuring that CBF matches metabolic demand.

Key metabolites:

When perfusion pressure falls, tissue oxygen decreases and metabolic byproducts accumulate, causing vasodilation to restore flow. This is a slower mechanism (10-30 seconds) than the myogenic response.

3. Neurogenic Mechanism

The cerebral circulation receives sympathetic innervation from the superior cervical ganglion via perivascular nerves. While neurogenic control is less dominant than in the systemic circulation, it plays an important role in protecting the brain from extremes of pressure.

Sympathetic innervation:

• Norepinephrine release causes vasoconstriction via alpha-1 receptors
• Protects against breakthrough hyperaemia at high pressures
• Rightward shift of autoregulation curve in chronic hypertension
• Denervation lowers ULA, increasing vulnerability to acute hypertension

Parasympathetic innervation:

• Vagal and facial nerve contributions
• Vasodilatory effect via nitric oxide and VIP
• Less well characterised clinically

Intrinsic neurogenic control:

• Perivascular nerves release NO, CGRP, VIP
• Modulate vascular tone locally
• Contribute to functional hyperaemia (PMID: 15159348)

4. Endothelial Mechanism

The vascular endothelium produces vasoactive substances that modulate cerebral vascular tone:

• Nitric oxide (NO): Constitutively produced by eNOS; causes vasodilation; tonically active
• Prostacyclin (PGI2): Vasodilator produced by COX
• Endothelin-1 (ET-1): Potent vasoconstrictor; balance with NO determines tone
• Endothelium-derived hyperpolarising factor (EDHF): K+ channel-mediated vasodilation

Endothelial dysfunction (injury, sepsis, aging) impairs autoregulation and flow-metabolism coupling (PMID: 17991892).

Impaired Autoregulation

Autoregulation is impaired in numerous pathological conditions, making CBF pressure-passive and vulnerable to systemic blood pressure changes.

Conditions causing impaired autoregulation:

Traumatic Brain Injury (TBI)

Autoregulation is impaired in approximately 50-60% of severe TBI patients. Loss of autoregulation is associated with:

• Higher ICP
• Worse neurological outcomes
• Increased mortality

The Brain Trauma Foundation guidelines recommend maintaining CPP 60-70 mmHg in severe TBI, with avoidance of CPP less than 50 mmHg (associated with ischaemia) and greater than 70 mmHg (associated with ARDS without outcome benefit) (PMID: 27654000).

Optimal CPP (CPPopt) is the CPP at which autoregulatory capacity is maximal. Monitoring autoregulation (using pressure reactivity index, PRx) and targeting CPPopt has been associated with improved outcomes in observational studies (PMID: 22366777).

---

Carbon Dioxide Reactivity

Relationship Between PaCO2 and CBF

Carbon dioxide is the most potent physiological regulator of cerebral vascular tone. CBF changes linearly with PaCO2 within the physiological range (20-80 mmHg) (PMID: 13645234).

CO2 reactivity:

• Magnitude: CBF changes 3-4% per mmHg change in PaCO2 (approximately 2 mL/100g/min per mmHg)
• Range: Linear relationship between PaCO2 20-80 mmHg
• Direction: Hypercapnia causes vasodilation; hypocapnia causes vasoconstriction
• Response time: Begins within seconds; maximal effect at 2-5 minutes
• Duration: Sustained as long as PaCO2 change maintained; renal bicarbonate compensation over 6-12 hours

Graphical representation:

At PaCO2 40 mmHg: CBF = 50 mL/100g/min At PaCO2 20 mmHg: CBF = 25 mL/100g/min (50% reduction) At PaCO2 80 mmHg: CBF = 100 mL/100g/min (100% increase)

Mechanism of CO2 Reactivity

CO2 crosses the blood-brain barrier freely by diffusion. The vasoactive effect is mediated by hydrogen ions (H+) in the perivascular space, not CO2 directly.

Mechanism:

1. CO2 diffuses across BBB into brain extracellular fluid
2. Carbonic anhydrase catalyses: CO2 + H2O leads to H2CO3 leads to H+ + HCO3-
3. H+ ions cause smooth muscle relaxation via:
   • Inhibition of voltage-gated Ca2+ channels
   • Activation of K+ channels (hyperpolarisation)
   • Prostanoid release from endothelium
   • Nitric oxide release
4. Vascular smooth muscle relaxation causes vasodilation and increased CBF

The pH of brain ECF (normally 7.32) is the key regulator. Metabolic acidosis with the same pH change causes less vasodilation because H+ ions do not cross the BBB as readily as CO2. Conversely, CSF acidosis from hypercapnia causes more pronounced vasodilation than arterial acidosis (PMID: 6334087).

Chronic changes:

Over 6-12 hours, renal compensation normalises blood pH through bicarbonate retention (hypocapnia) or excretion (hypercapnia). The CSF pH also normalises through choroid plexus bicarbonate transport. This explains why:

• Chronic hyperventilation loses its CBF-reducing effect over 12-24 hours
• Rapid normalisation of PaCO2 after chronic hyperventilation causes rebound cerebral vasodilation and ICP elevation (PMID: 9892257)

Clinical Applications

Hyperventilation in TBI:

Hyperventilation was historically used to reduce ICP through CBF reduction. However, evidence has shown:

• Hyperventilation to PaCO2 less than 25 mmHg causes cerebral ischaemia (PMID: 9044923)
• Prophylactic hyperventilation worsens outcomes at 3-6 months
• Brief hyperventilation (PaCO2 30-35 mmHg) may be used for acute ICP crises as a bridge to definitive therapy
• Brain tissue oxygen (PbtO2) monitoring reveals ischaemia during aggressive hyperventilation

Brain Trauma Foundation recommendations (PMID: 27654000):

• Avoid prophylactic hyperventilation (PaCO2 less than or equal to 25 mmHg)
• Brief hyperventilation acceptable for acute ICP crises
• Target normocapnia (PaCO2 35-40 mmHg) as default
• Consider PbtO2 monitoring if using hyperventilation

Permissive hypercapnia:

In patients with ARDS and brain injury, the need for lung-protective ventilation (low tidal volumes) may conflict with the desire for normocapnia. Moderate hypercapnia (PaCO2 50-60 mmHg) is generally tolerated if:

• ICP is monitored and controlled
• Hypercapnia develops gradually (allowing CSF pH buffering)
• CPP is maintained

Hypocapnia during general anaesthesia:

Hyperventilation during anaesthesia reduces CBF and brain bulk, facilitating surgical access. However:

• Moderate hyperventilation (PaCO2 30-35 mmHg) is safe
• Severe hyperventilation (PaCO2 less than 25 mmHg) may cause ischaemia, especially in patients with cerebrovascular disease
• Effect is temporary due to CSF pH compensation

---

Oxygen Effects on CBF

Hypoxic Vasodilation

Oxygen has relatively little effect on CBF within the normal physiological range. CBF remains stable until PaO2 falls below approximately 50 mmHg (6.7 kPa), at which point significant vasodilation occurs.

Oxygen reactivity:

Mechanism of hypoxic vasodilation:

1. Adenosine release: Hypoxia depletes ATP, producing adenosine which causes vasodilation via A2A receptors
2. KATP channel opening: ATP depletion opens KATP channels, hyperpolarising smooth muscle
3. Nitric oxide: Hypoxia stimulates NO production from endothelium and neurons
4. Lactate and H+: Anaerobic metabolism produces acidic metabolites
5. Direct smooth muscle effect: Hypoxia directly relaxes vascular smooth muscle

The threshold for hypoxic vasodilation (PaO2 50 mmHg) corresponds to the steep portion of the oxyhaemoglobin dissociation curve, where small reductions in PaO2 cause significant desaturation. This represents a critical safety mechanism, increasing oxygen delivery when content falls (PMID: 6334087).

Hyperoxia

High inspired oxygen concentrations (FiO2 1.0) cause mild cerebral vasoconstriction (10-15% CBF reduction). This is generally clinically insignificant but should be considered in patients with:

• Traumatic brain injury (may be beneficial or harmful depending on circumstances)
• Stroke (potential for oxygen toxicity vs ischaemia prevention)
• Carbon monoxide poisoning (hyperbaric oxygen therapy)

Hyperbaric oxygen:

At pressures of 2-3 atmospheres with 100% O2:

• Significant CBF reduction (25-30%)
• Increased dissolved oxygen compensates for reduced flow
• Used therapeutically for CO poisoning, necrotising fasciitis, decompression illness

Clinical Implications

Oxygen therapy in brain injury:

The optimal oxygenation target in brain-injured patients is uncertain:

• Hypoxia (PaO2 less than 60 mmHg): Universally harmful; must be avoided
• Normoxia (PaO2 80-100 mmHg): Traditional target
• Hyperoxia (PaO2 greater than 150 mmHg): Potential for oxidative stress; uncertain benefit
• PbtO2 greater than 20 mmHg: Brain tissue oxygen target in TBI (BOOST-II trial, PMID: 29136083)

The BOOST-II trial demonstrated that a management protocol incorporating brain tissue oxygen (PbtO2) monitoring reduced brain hypoxia compared to ICP monitoring alone and showed a trend toward improved outcomes (PMID: 29136083).

---

Intracranial Pressure

Monro-Kellie Doctrine

The Monro-Kellie doctrine, articulated by Alexander Monro (1783) and George Kellie (1824) and refined by Harvey Cushing, states that the total volume within the rigid adult cranium is fixed, so an increase in any one component must be compensated by a decrease in another.

Intracranial components:

Compensatory mechanisms:

When an additional volume (e.g., haematoma, oedema, tumour) develops:

1. CSF displacement: First line; CSF moves from cranial to spinal subarachnoid space (50-70 mL capacity)
2. Reduced CSF production: Choroid plexus reduces production (normally 0.3-0.5 mL/min, 500 mL/day)
3. Increased CSF absorption: Enhanced absorption via arachnoid granulations
4. Venous blood displacement: Compression of low-pressure venous sinuses
5. Brain tissue deformation: Ultimately, brain tissue is displaced (herniation syndromes)

Pressure-volume relationship:

The intracranial pressure-volume relationship is exponential, not linear. Initially, compensatory mechanisms maintain normal ICP despite volume increases. Once reserves are exhausted, small additional volumes cause large ICP increases.

Elastance = dP/dV (change in pressure per unit volume change) Compliance = dV/dP (reciprocal of elastance)

Normal intracranial compliance allows addition of 10-15 mL before ICP rises significantly. With reduced compliance, even 1-2 mL causes ICP elevation (PMID: 27418377).

Normal ICP and Measurement

Normal ICP values:

ICP monitoring indications (Brain Trauma Foundation):

• Severe TBI (GCS 3-8) with abnormal CT scan
• Severe TBI with normal CT if 2 or more of: age greater than 40 years, unilateral/bilateral motor posturing, SBP less than 90 mmHg

ICP monitoring techniques:

ICP Waveforms

The ICP waveform reflects cardiac pulsations transmitted to the intracranial contents. Normal ICP has three peaks:

Normal ICP waveform components:

1. P1 (Percussion wave): Sharp peak reflecting arterial pulsation; amplitude 1-3 mmHg
2. P2 (Tidal wave): Reflects intracranial compliance; amplitude normally less than P1
3. P3 (Dicrotic wave): Reflects aortic valve closure (dicrotic notch)

Normal pattern: P1 greater than P2 greater than P3

Pathological ICP waveforms:

When intracranial compliance is reduced:

• P2 amplitude increases relative to P1
• P2 greater than P1: Indicates reduced compliance
• Waveform becomes more rounded, loses distinct peaks
• Suggests increased risk of ICP crisis

Lundberg Waves:

Erik Lundberg (1960) described three types of slow ICP oscillations (PMID: 13729328):

A waves (plateau waves) are medical emergencies indicating critically reduced intracranial compliance. They result from:

1. Slight ICP increase leads to decreased CPP
2. Autoregulatory vasodilation to maintain CBF
3. Increased CBV further raises ICP
4. Positive feedback loop until ICP markedly elevated
5. Terminates when autoregulation fails or intervention occurs

Cerebral Perfusion Pressure

CPP calculation:

CPP = MAP - ICP

Where:

• MAP = Mean arterial pressure (measured at the level of the tragus/external auditory meatus in supine patients)
• ICP = Intracranial pressure

If CVP exceeds ICP (rare, e.g., severe heart failure), then: CPP = MAP - CVP

CPP targets in TBI (Brain Trauma Foundation, 2016):

Optimal CPP (CPPopt):

The concept of CPPopt proposes that there is an individualised CPP at which autoregulation is most effective. This can be identified using:

• Pressure Reactivity Index (PRx): Correlation coefficient between slow waves of MAP and ICP
  • "PRx less than 0: Intact autoregulation (ICP decreases as MAP increases)"
  • "PRx greater than 0.25: Impaired autoregulation (ICP passively follows MAP)"

CPPopt is the CPP at which PRx is most negative (best autoregulation). Targeting CPPopt has been associated with improved outcomes in observational studies, though RCT evidence is awaited (COGiTATE trial) (PMID: 31551435).

---

Blood-Brain Barrier

Structure

The blood-brain barrier (BBB) is a selective permeability barrier that separates circulating blood from brain extracellular fluid. It maintains ionic homeostasis, excludes pathogens and toxins, and regulates drug entry.

BBB components:

1. Cerebral endothelial cells: Continuous endothelium with tight junctions (zonulae occludentes)
2. Basement membrane: Extracellular matrix providing structural support
3. Pericytes: Embedded in basement membrane; regulate endothelial function and angiogenesis
4. Astrocytic endfeet: Cover greater than 99% of capillary surface; induce and maintain BBB properties

Tight junctions:

Tight junctions between endothelial cells are the primary barrier. They consist of:

• Claudins (claudin-3, -5, -12): Transmembrane proteins forming the seal
• Occludin: Transmembrane protein regulating permeability
• Junctional adhesion molecules (JAMs): Immunoglobulin superfamily members
• Zona occludens proteins (ZO-1, ZO-2, ZO-3): Cytoplasmic scaffolding proteins linking junctions to actin cytoskeleton

These junctions have electrical resistance of 1500-2000 ohm.cm2, compared to 3-30 ohm.cm2 in peripheral capillaries (PMID: 16306869).

BBB Transport

The BBB is not an absolute barrier but a regulatory interface with multiple transport mechanisms:

Transport mechanisms:

Drug penetration factors:

• Lipophilicity: Log P greater than 2 favours penetration
• Molecular weight: Less than 400-500 Da crosses more readily
• Protein binding: Only free drug crosses
• P-glycoprotein substrate: Actively expelled from brain
• Ionisation: Non-ionised forms cross more readily

BBB Dysfunction

BBB breakdown occurs in numerous pathological conditions, allowing extravasation of plasma proteins, inflammatory cells, and normally excluded substances.

Causes of BBB dysfunction:

Clinical implications:

BBB breakdown:

• Allows normally excluded drugs to enter brain (may be therapeutic or toxic)
• Causes vasogenic oedema (increased brain water in extracellular space)
• Enables contrast enhancement on CT/MRI (diagnostic utility)
• May worsen with mannitol (if barrier disrupted, mannitol enters brain and causes reverse osmotic gradient)

---

Cerebral Venous Drainage

Venous Anatomy

Cerebral venous drainage is valveless and ultimately flows into the internal jugular veins. Understanding venous anatomy is essential for interpreting jugular venous oximetry and managing conditions affecting venous outflow.

Superficial venous system:

• Superior sagittal sinus drains superficial cortical veins
• Drains posteriorly to confluence of sinuses (torcular Herophili)

Deep venous system:

• Internal cerebral veins drain deep structures (thalami, basal ganglia)
• Join to form great vein of Galen
• Drains to straight sinus, then confluence of sinuses

Dural venous sinuses:

• Superior sagittal sinus leads to confluence leads to transverse sinuses leads to sigmoid sinuses leads to internal jugular veins
• Cavernous sinuses drain anterior structures; connect to pterygoid plexus and ultimately internal jugular veins
• Occipital sinus and marginal sinus connect to vertebral venous plexus

Jugular Bulb Oximetry

The jugular bulb is the dilated portion of the internal jugular vein just below the skull base. Jugular venous oxygen saturation (SjvO2) reflects global cerebral oxygen extraction.

Normal SjvO2: 55-75%

Interpretation:

AVDO2 calculation:

AVDO2 = CaO2 - CjvO2 = Hb x 1.34 x (SaO2 - SjvO2) + 0.003 x (PaO2 - PjvO2)

Normal AVDO2: 5-7 mL O2/100mL blood

Oxygen extraction ratio (O2ER):

O2ER = AVDO2 / CaO2 = (SaO2 - SjvO2) / SaO2

Normal O2ER: 25-35%

Clinical applications:

• Monitoring cerebral oxygenation in TBI
• Detecting cerebral ischaemia during hyperventilation
• Guiding CPP optimisation
• Assessing flow-metabolism coupling

Limitations:

• Global measure; may miss regional ischaemia
• Catheter malposition (venous contamination from face)
• Right vs left jugular (dominant side drains more brain volume)
• Continuous monitoring requires fibreoptic catheter

---

Temperature Effects

Temperature and CBF

Temperature profoundly affects cerebral metabolism and blood flow. The relationship between temperature and CMRO2 is described by Q10 (the factor by which metabolic rate changes per 10 degrees Celsius temperature change).

Q10 for brain: Approximately 2-2.5

This means:

• 10 degrees Celsius decrease leads to 50-60% CMRO2 reduction
• 1 degree Celsius decrease leads to approximately 6-7% CMRO2 reduction

Because of flow-metabolism coupling, CBF decreases proportionally with temperature reduction.

Temperature effects on cerebral physiology:

Targeted Temperature Management

Post-cardiac arrest:

The TTM (Targeted Temperature Management) trial (PMID: 24237006) and TTM2 trial (PMID: 33197436) have informed current practice:

• TTM1 (2013): 33 degrees Celsius vs 36 degrees Celsius showed no difference in outcomes
• TTM2 (2021): 33 degrees Celsius vs normothermia (37.5 degrees Celsius) showed no difference

Current recommendations:

• Avoid hyperthermia (temperature greater than 37.7 degrees Celsius) for 72 hours post-ROSC
• Active temperature management (32-36 degrees Celsius) for comatose patients post-ROSC
• Select and maintain target consistently

Traumatic brain injury:

The Eurotherm3235 trial (PMID: 26444221) found that prophylactic hypothermia (32-35 degrees Celsius) for 48+ hours in TBI worsened outcomes compared to normothermia. Current practice:

• Avoid hyperthermia (aggressive treatment of fever)
• No prophylactic hypothermia
• Brief hypothermia may be used for refractory ICP elevation

Effects on cerebral autoregulation:

Hypothermia generally preserves autoregulation, but extreme hypothermia (less than 28 degrees Celsius) may impair autoregulatory responses. Rewarming can trigger hyperaemia and ICP elevation if not performed gradually (PMID: 19204212).

---

Pharmacological Effects

Sedative Agents

Sedative agents have profound effects on cerebral metabolism, blood flow, and ICP. Understanding these effects is essential for managing neurocritical care patients.

Effects of sedative agents on cerebral physiology:

Propofol:

• Reduces CMRO2 and CBF in coupled fashion
• Maximum metabolic suppression at burst suppression (isoelectric EEG is not more protective)
• Preserves autoregulation and CO2 reactivity
• Causes hypotension (may reduce CPP if not managed)
• Risk of propofol infusion syndrome with prolonged high-dose use (PMID: 19399536)

Barbiturates (thiopental/pentobarbital):

• Potent CMRO2 and CBF reducers
• Used for refractory ICP elevation (barbiturate coma)
• Maximum benefit at EEG burst suppression
• Prolonged elimination; requires cardiovascular support
• Associated with infection risk and prolonged ICU stay (PMID: 27654000)

Ketamine:

Traditional teaching suggests ketamine increases ICP due to increased CBF. However, recent evidence suggests this is less significant than previously believed, especially when:

• Mechanical ventilation controls PaCO2
• Concurrent sedation with GABA-ergic agents
• Patient is volume-resuscitated

Ketamine may be acceptable in brain-injured patients with appropriate monitoring (PMID: 25680659).

Vasopressors

Effects of vasopressors on cerebral circulation:

Clinical considerations:

In patients with impaired autoregulation, increasing MAP with vasopressors will increase CBF (and possibly ICP). This may be beneficial (if CBF was inadequate) or harmful (if hyperaemia results).

Blood-brain barrier permeability to catecholamines is normally very low, so direct CNS effects are minimal. However, BBB dysfunction may allow penetration, and high circulating catecholamine levels may have indirect effects via systemic responses (PMID: 12719279).

Osmotic Agents

Mannitol:

Mannitol (20%) reduces ICP through:

1. Immediate rheological effect: Reduces blood viscosity leads to reduced CBV leads to reduced ICP (within minutes)
2. Osmotic gradient: Draws water from brain to blood across intact BBB (peaks at 20-60 minutes)

Dose: 0.25-1 g/kg IV bolus Onset: 5-10 minutes Duration: 2-6 hours

Precautions:

• Serum osmolality greater than 320 mOsm/kg associated with renal toxicity
• May cross disrupted BBB and worsen oedema (reverse osmotic shift)
• Diuretic effect may cause hypovolaemia and hypotension

Hypertonic saline:

Hypertonic saline (3-23.4%) reduces ICP through:

1. Osmotic gradient (similar to mannitol)
2. Reduced endothelial cell swelling
3. Improved blood rheology
4. Immunomodulatory effects

Advantages over mannitol:

• No renal threshold for effect
• Volume expansion rather than depletion
• May be effective when mannitol fails
• Can be given peripherally (3%) or centrally (23.4%)

Dose: 3% NaCl 250-500 mL; 23.4% NaCl 30 mL bolus Monitor: Serum Na+ (target 145-155 mmol/L for refractory ICP)

PMID: 27654000 (Brain Trauma Foundation): No recommendation on mannitol vs hypertonic saline due to insufficient evidence.

---

Clinical Applications

Traumatic Brain Injury

Primary injury occurs at the moment of impact and is not modifiable. Secondary injury develops over hours to days from hypoxia, hypotension, oedema, and ischaemia; this is the target of neurocritical care.

Brain Trauma Foundation Guidelines (4th Edition, 2016):

Tiered approach to ICP management:

Tier 0: Prevention

• Head elevation 30 degrees
• Midline neck position
• Avoid hyperthermia, hypoxia, hypotension, hypercapnia
• Adequate sedation and analgesia
• Seizure prophylaxis

Tier 1: First-line interventions

• CSF drainage (if EVD in place)
• Osmotherapy (mannitol or hypertonic saline)
• Increase sedation
• Optimise PaCO2 (35-40 mmHg)

Tier 2: Second-line interventions

• Mild hyperventilation (PaCO2 30-35 mmHg) as bridge
• Neuromuscular blockade
• Consider repeat CT and surgical evaluation

Tier 3: Rescue therapies

• Barbiturate coma (burst suppression)
• Decompressive craniectomy
• Moderate hypothermia (32-35 degrees Celsius)

BOOST-II Trial (PMID: 29136083):

This phase II trial demonstrated that a protocol incorporating brain tissue oxygen (PbtO2) monitoring in addition to ICP monitoring reduced brain hypoxia compared to ICP monitoring alone. There was a trend toward improved functional outcomes, supporting the use of multimodal neuromonitoring.

Subarachnoid Haemorrhage

SAH disrupts autoregulation and carries risks of:

• Delayed cerebral ischaemia (DCI): 30% of patients; peaks days 4-14
• Vasospasm: Angiographic narrowing; correlates with DCI
• Cerebral oedema: Early and late phases

Management principles:

• Nimodipine 60 mg Q4H PO for 21 days (only proven intervention to reduce DCI)
• Euvolaemia (avoid both hypovolaemia and hypervolaemia)
• Maintain CPP greater than 70 mmHg (higher threshold than TBI due to vasospasm)
• Induced hypertension for symptomatic vasospasm (SBP 160-200 mmHg)
• Consider angioplasty or intra-arterial vasodilators for refractory vasospasm

Ischaemic Stroke

Acute phase (0-24 hours):

Autoregulation is impaired in ischaemic penumbra. Blood pressure management is critical:

• No thrombolysis: Permissive hypertension; treat only if BP greater than 220/120 mmHg
• Thrombolysis candidates: BP less than 185/110 mmHg before treatment; less than 180/105 after
• Mechanical thrombectomy: Similar targets; individualized based on collaterals

Aggressive BP lowering in acute stroke may extend infarct by reducing penumbral perfusion.

Subacute/chronic:

Autoregulation recovers over days to weeks. Gradual blood pressure reduction to chronic targets is appropriate.

Australian/New Zealand Context

Indigenous Health Considerations:

Aboriginal and Torres Strait Islander Australians and Maori New Zealanders have significantly higher rates of:

• Stroke (2-3x higher incidence)
• Traumatic brain injury (2x higher incidence)
• Diabetes and hypertension (risk factors for cerebrovascular disease)

Specific considerations:

1. Remote and rural challenges: Many TBI and stroke patients present from remote communities

   • Prolonged transport times (may exceed 6 hours)
   • Limited pre-hospital capabilities
   • RFDS retrieval protocols

2. Cultural considerations:

   • Family (whanau) involvement in decision-making
   • Traditional healers and cultural practices
   • Understanding of "sorry business" and end-of-life practices
   • Use of Aboriginal Health Workers/Liaison Officers

3. Health literacy:

   • Plain language explanations
   • Visual aids and interpreters
   • Community engagement for secondary prevention

4. Outcomes disparities:

   • Later presentation to care
   • Less access to specialised neurocritical care
   • Higher mortality from TBI and stroke

Retrieval considerations:

RFDS and state retrieval services (NSW Ambulance, QAS, Ambulance Victoria, SAAS) have specific protocols for:

• Intubation and ventilation targets
• Blood pressure management during transport
• ICP management without monitoring
• Time-critical transfer decisions

---

SAQ Practice Questions

SAQ 1: Cerebral Blood Flow and Autoregulation (15 marks)

Question:

A 45-year-old man is admitted to ICU following severe traumatic brain injury. His initial GCS was 6 (E1V2M3). CT shows bifrontal contusions with moderate cerebral oedema. An EVD has been inserted.

Current parameters: MAP 85 mmHg, ICP 18 mmHg, PaCO2 38 mmHg, PaO2 95 mmHg, Temperature 37.2 degrees Celsius.

a) Calculate the cerebral perfusion pressure and comment on its adequacy. (2 marks)

b) Describe the mechanisms of cerebral autoregulation and explain why it may be impaired in this patient. (5 marks)

c) Outline the relationship between PaCO2 and cerebral blood flow, including the mechanism. (4 marks)

d) Describe the tiered approach to managing elevated ICP if it rises to 28 mmHg. (4 marks)

---

Model Answer:

a) CPP calculation (2 marks)

CPP = MAP - ICP = 85 - 18 = 67 mmHg

This CPP of 67 mmHg is adequate, falling within the Brain Trauma Foundation recommended range of 60-70 mmHg for severe TBI (PMID: 27654000). Values below 60 mmHg are associated with cerebral ischaemia, while values above 70 mmHg may increase risk of ARDS without improving neurological outcomes.

b) Mechanisms of autoregulation and impairment (5 marks)

Mechanisms of cerebral autoregulation:

1. Myogenic mechanism (Bayliss effect): Vascular smooth muscle intrinsically contracts in response to stretch (increased transmural pressure) and relaxes with reduced stretch. Operates via stretch-activated cation channels and voltage-gated calcium channels.

2. Metabolic mechanism: Tissue hypoxia and accumulation of metabolic byproducts (CO2, H+, adenosine, K+, lactate) cause vasodilation to increase flow. Conversely, reduced metabolism leads to vasoconstriction.

3. Neurogenic mechanism: Sympathetic innervation from superior cervical ganglion modulates vascular tone. Protects against breakthrough hyperaemia at high pressures.

4. Endothelial mechanism: Nitric oxide, prostacyclin, and endothelin-1 regulate vascular tone. Shear stress stimulates NO production and vasodilation.

Why autoregulation is impaired in this patient:

• Mechanical disruption of blood vessels from primary injury
• Blood-brain barrier breakdown allows extravasation of vasoactive substances
• Local inflammation impairs endothelial function
• Stretch-sensitive ion channels may be damaged
• Metabolic derangement in pericontusional tissue
• Approximately 50-60% of severe TBI patients have impaired autoregulation
• Loss of autoregulation makes CBF pressure-passive, increasing vulnerability to MAP changes

c) PaCO2 and CBF relationship (4 marks)

Quantitative relationship:

• CBF changes 3-4% per mmHg change in PaCO2 (approximately 2 mL/100g/min per mmHg)
• Linear relationship between PaCO2 20-80 mmHg
• At PaCO2 40 mmHg: CBF approximately 50 mL/100g/min
• At PaCO2 20 mmHg: CBF approximately 25 mL/100g/min (50% reduction)
• At PaCO2 80 mmHg: CBF approximately 100 mL/100g/min (100% increase)

Mechanism:

1. CO2 freely diffuses across blood-brain barrier
2. In brain ECF, carbonic anhydrase catalyzes: CO2 + H2O leads to H2CO3 leads to H+ + HCO3-
3. H+ ions are the vasoactive species (not CO2 directly)
4. H+ causes smooth muscle relaxation via:
   • Inhibition of voltage-gated Ca2+ channels
   • Activation of K+ channels (hyperpolarisation)
   • Stimulation of NO and prostanoid release
5. Effect attenuates over 12-24 hours due to CSF pH normalisation

d) Tiered approach to elevated ICP (4 marks)

Tier 0 (Prevention/Optimisation):

• Head elevation 30 degrees, midline position
• Avoid hyperthermia, hypoxia, hypercapnia
• Ensure adequate sedation and analgesia
• Loosen cervical collar if present
• Check for seizure activity

Tier 1 (First-line interventions):

• CSF drainage via EVD (10-20 mL)
• Osmotherapy: Mannitol 0.5-1 g/kg IV or hypertonic saline 3% 250 mL
• Increase propofol sedation
• Optimise PaCO2 to 35-40 mmHg
• Consider neuromuscular blockade

Tier 2 (Second-line interventions):

• Mild hyperventilation (PaCO2 30-35 mmHg) as bridge therapy
• Repeat CT to evaluate for surgical lesion
• Continuous neuromuscular blockade if not already initiated

Tier 3 (Rescue therapies):

• Barbiturate coma (thiopental/pentobarbital to EEG burst suppression)
• Decompressive craniectomy
• Moderate hypothermia (32-35 degrees Celsius)

---

SAQ 2: Monro-Kellie Doctrine and ICP Dynamics (15 marks)

Question:

A 28-year-old woman presents following sudden-onset severe headache. CT demonstrates subarachnoid haemorrhage (Fisher grade 3). She is intubated for airway protection. ICP monitoring is commenced.

a) Describe the Monro-Kellie doctrine and the components of intracranial volume. (3 marks)

b) Explain the concepts of intracranial compliance and elastance. What happens to these as ICP rises? (4 marks)

c) Describe the normal ICP waveform and how it changes with reduced compliance. (4 marks)

d) Outline Lundberg's classification of ICP waves and their clinical significance. (4 marks)

---

Model Answer:

a) Monro-Kellie doctrine (3 marks)

The Monro-Kellie doctrine states that the total volume within the rigid adult cranium is fixed. An increase in any one intracranial component must be compensated by a decrease in one or more other components to maintain constant volume.

Intracranial volume components:

Compensatory mechanisms:

1. CSF displacement from cranial to spinal subarachnoid space (50-70 mL capacity)
2. Reduced CSF production by choroid plexus
3. Increased CSF absorption via arachnoid granulations
4. Compression of venous sinuses and venous blood displacement
5. (Ultimate) Brain tissue displacement (herniation syndromes)

b) Compliance and elastance (4 marks)

Compliance (C): The change in volume per unit change in pressure. C = dV/dP (units: mL/mmHg)

Elastance (E): The change in pressure per unit change in volume (reciprocal of compliance). E = dP/dV (units: mmHg/mL)

The intracranial pressure-volume relationship is exponential, not linear:

• Initially, compensatory mechanisms maintain normal ICP despite volume increases (high compliance, low elastance)
• As reserves exhaust, small additional volumes cause large ICP rises (low compliance, high elastance)

Changes as ICP rises:

• Compliance decreases: Less volume change tolerated per mmHg
• Elastance increases: Each mL of additional volume causes greater pressure rise
• Compensatory reserve exhausted
• System operates on steep portion of pressure-volume curve
• Small changes (coughing, position change) cause large ICP spikes
• Eventually, herniation occurs

Clinical assessment:

• Pressure-volume index (PVI): Volume required to increase ICP 10-fold
• Normal PVI: 25-30 mL
• Reduced PVI: Less than 15 mL (poor compliance)
• Tested by injecting/withdrawing known CSF volumes through EVD

c) ICP waveform (4 marks)

Normal ICP waveform components:

The ICP waveform reflects arterial pulsations transmitted to intracranial contents and has three characteristic peaks:

1. P1 (Percussion wave): Sharp peak reflecting arterial pulsation during systole; amplitude 1-3 mmHg

2. P2 (Tidal wave): Reflects intracranial compliance; brain tissue deformation following arterial pulse

3. P3 (Dicrotic wave): Corresponds to dicrotic notch of arterial waveform (aortic valve closure)

Normal pattern: P1 greater than P2 greater than P3 (descending staircase)

Changes with reduced compliance:

When intracranial compliance is reduced:

• P2 amplitude increases relative to P1
• Pathological pattern: P2 greater than or equal to P1
• Waveform becomes more rounded
• Individual peaks become less distinct
• Overall waveform amplitude increases
• Reflects decreased ability to accommodate arterial pulsations
• Indicates increased risk of ICP crisis
• "Saw-tooth" appearance in severe cases

d) Lundberg waves (4 marks)

Erik Lundberg (1960) described three types of slow ICP oscillations with different clinical significance:

A waves (plateau waves) mechanism:

1. Initial slight ICP increase (any cause)
2. Reduced CPP (CPP = MAP - ICP)
3. Autoregulatory cerebral vasodilation to maintain CBF
4. Increased cerebral blood volume raises ICP further
5. Positive feedback loop continues
6. ICP reaches plateau (50-100 mmHg) for 5-20 minutes
7. Terminates when:
   • Autoregulation fails
   • Vasopressor response increases MAP
   • Spontaneous CSF displacement occurs
   • Intervention occurs

Clinical response to A waves:

• Immediate intervention required
• Increase MAP to restore CPP
• CSF drainage if EVD present
• Osmotherapy
• Brief hyperventilation as bridge
• Evaluate for surgical lesion

---

Viva Scenarios

Viva Scenario 1: Cerebral Blood Flow Physiology (20 marks)

Opening Stem:

You are asked to examine a 55-year-old man in ICU following severe traumatic brain injury. He has an EVD and ICP monitoring in situ.

---

Examiner: Before we discuss this patient, tell me about normal cerebral blood flow.

Candidate: Normal global cerebral blood flow is approximately 50 mL/100g/min, equating to 700-750 mL/min total. This represents about 15% of cardiac output despite the brain being only 2% of body weight. Grey matter receives 80-100 mL/100g/min while white matter receives 20-25 mL/100g/min, a 4:1 ratio reflecting their different metabolic demands.

Examiner: How was this first measured in humans?

Candidate: Kety and Schmidt developed the first quantitative method in 1948, published in the Journal of Clinical Investigation. They used the Fick principle with nitrous oxide as a diffusible tracer. Subjects inhaled 15% N2O for 10-15 minutes while arterial and jugular venous blood samples were taken. CBF was calculated from the tissue uptake of N2O and the arteriovenous difference. They established normal values of 54 mL/100g/min for CBF and 3.5 mL O2/100g/min for CMRO2.

Examiner: Good. What is cerebral autoregulation?

Candidate: Cerebral autoregulation is the intrinsic ability of cerebral blood vessels to maintain relatively constant CBF despite changes in cerebral perfusion pressure or mean arterial pressure. Lassen's classic 1959 curve suggested a plateau region between MAP 50-150 mmHg, though more recent evidence from Brassard and colleagues suggests a narrower range of approximately 60-90 mmHg in healthy individuals.

Examiner: What are the mechanisms of autoregulation?

Candidate: There are four main mechanisms:

First, the myogenic mechanism or Bayliss effect, where vascular smooth muscle intrinsically contracts in response to stretch and relaxes when stretch is reduced. This operates via stretch-activated cation channels and voltage-gated calcium channels and is the dominant mechanism for rapid responses, acting within 5-10 seconds.

Second, the metabolic mechanism, where tissue hypoxia and metabolite accumulation, including CO2, hydrogen ions, adenosine, and potassium, cause vasodilation to restore flow. This is a slower mechanism, taking 10-30 seconds.

Third, the neurogenic mechanism, involving sympathetic innervation from the superior cervical ganglion. This protects against breakthrough hyperaemia at high pressures and contributes to the rightward shift seen in chronic hypertension.

Fourth, the endothelial mechanism, involving nitric oxide, prostacyclin, and endothelin-1 regulating vascular tone in response to shear stress and vasoactive mediators.

Examiner: How does carbon dioxide affect cerebral blood flow?

Candidate: CO2 is the most potent physiological regulator of cerebral vascular tone. CBF changes 3-4% per mmHg change in PaCO2, approximately 2 mL/100g/min per mmHg. This relationship is linear between PaCO2 20-80 mmHg.

The mechanism involves CO2 freely diffusing across the blood-brain barrier, where carbonic anhydrase catalyses its conversion to carbonic acid, then to hydrogen ions and bicarbonate. Hydrogen ions are the actual vasoactive species, causing smooth muscle relaxation through inhibition of voltage-gated calcium channels, activation of potassium channels, and stimulation of NO and prostanoid release.

This effect attenuates over 12-24 hours as CSF pH normalises through bicarbonate transport at the choroid plexus.

Examiner: What about oxygen?

Candidate: Oxygen has relatively little effect on CBF within the normal physiological range. CBF remains stable until PaO2 falls below approximately 50 mmHg, at which point significant vasodilation occurs. This threshold corresponds to the steep portion of the oxyhaemoglobin dissociation curve.

The mechanism involves adenosine release from ATP depletion, KATP channel opening, nitric oxide production, and direct smooth muscle effects.

Conversely, hyperoxia causes mild vasoconstriction of 10-15%, which is generally clinically insignificant.

Examiner: This patient has impaired autoregulation. How is that assessed?

Candidate: Autoregulation can be assessed using several methods:

The pressure reactivity index, or PRx, is the correlation coefficient between slow waves of MAP and ICP. A negative PRx indicates intact autoregulation where ICP decreases as MAP increases, while PRx greater than 0.25 indicates impaired autoregulation where ICP passively follows MAP.

The cerebrovascular resistance index, Mx, correlates MAP with middle cerebral artery flow velocity from transcranial Doppler. Similar interpretation to PRx.

Static and dynamic autoregulation testing involves inducing blood pressure changes and observing CBF response.

Near-infrared spectroscopy can assess regional cerebral oxygenation responses to pressure changes.

The concept of optimal CPP, or CPPopt, identifies the CPP at which PRx is most negative, representing best autoregulation. Targeting CPPopt has shown association with improved outcomes in observational studies.

Examiner: What pharmacological agents affect cerebral physiology and how?

Candidate: Sedative agents have significant effects. Propofol reduces CMRO2 and CBF by 30-50% in a coupled fashion, preserves autoregulation and CO2 reactivity, but causes hypotension which may reduce CPP. Maximum metabolic suppression occurs at burst suppression.

Barbiturates similarly reduce CMRO2 and CBF by 40-55% and are used for refractory ICP elevation.

Ketamine traditionally was thought to increase CBF and ICP, but recent evidence suggests this is less significant when PaCO2 is controlled and concurrent GABA-ergic sedation is used.

Volatile anaesthetics cause dose-dependent impairment of autoregulation and increase CBF at higher concentrations due to vasodilation.

Vasopressors like norepinephrine increase MAP and thus CPP; if autoregulation is intact, CBF remains stable, but with impaired autoregulation, CBF increases passively.

Osmotic agents reduce ICP through immediate rheological effects and subsequent osmotic gradient drawing water from brain to blood.

Examiner: Thank you. That concludes this station.

---

Viva Scenario 2: Intracranial Pressure Dynamics (20 marks)

Opening Stem:

A 32-year-old woman is admitted following aneurysmal subarachnoid haemorrhage. She deteriorates on day 7 with increasing drowsiness.

---

Examiner: What is the Monro-Kellie doctrine?

Candidate: The Monro-Kellie doctrine states that the total volume within the rigid adult cranium is fixed at approximately 1400-1700 mL. This volume comprises brain parenchyma at 80%, blood at 10%, and CSF at 10%. An increase in any one component must be compensated by a decrease in one or more other components to maintain constant total volume.

The compensatory mechanisms include CSF displacement from cranial to spinal subarachnoid space, which provides 50-70 mL capacity; reduced CSF production by the choroid plexus; increased CSF absorption via arachnoid granulations; and venous blood displacement by compression of the low-pressure venous sinuses. When these mechanisms are exhausted, brain tissue displacement occurs, leading to herniation syndromes.

Examiner: Explain intracranial compliance.

Candidate: Compliance is the change in volume per unit change in pressure, expressed as dV/dP in mL/mmHg. Elastance is the reciprocal, representing change in pressure per unit volume change.

The intracranial pressure-volume relationship is exponential, not linear. Initially, with adequate compensatory reserve, adding volume causes minimal pressure increase, representing high compliance and low elastance. As reserves exhaust, the system operates on the steep portion of the curve where small additional volumes cause large pressure increases, representing low compliance and high elastance.

This can be quantified using the pressure-volume index or PVI, which is the volume required to increase ICP 10-fold. Normal PVI is 25-30 mL; reduced PVI below 15 mL indicates poor compliance.

Examiner: Describe the normal ICP waveform.

Candidate: The normal ICP waveform reflects arterial pulsations transmitted to intracranial contents and has three characteristic peaks. P1, the percussion wave, is a sharp peak reflecting arterial pulsation during systole. P2, the tidal wave, reflects intracranial compliance and brain tissue deformation following the arterial pulse. P3, the dicrotic wave, corresponds to the dicrotic notch of the arterial waveform from aortic valve closure.

The normal pattern shows P1 greater than P2 greater than P3, creating a descending staircase appearance.

Examiner: How does this change with reduced compliance?

Candidate: With reduced intracranial compliance, P2 amplitude increases relative to P1, creating a pathological pattern where P2 equals or exceeds P1. The waveform becomes more rounded, individual peaks become less distinct, and overall amplitude increases. This reflects the decreased ability to accommodate arterial pulsations and indicates increased risk of an ICP crisis.

Examiner: Tell me about Lundberg waves.

Candidate: Erik Lundberg described three types of slow ICP oscillations in 1960.

A waves, also called plateau waves, have amplitude 50-100 mmHg and last 5-20 minutes. They occur irregularly and result from a vasodilatory cascade: a small ICP increase reduces CPP, triggering autoregulatory vasodilation which increases cerebral blood volume, further raising ICP in a positive feedback loop. A waves are pathological and indicate exhausted compensatory reserve with impending herniation. They require immediate intervention.

B waves have amplitude 10-20 mmHg and occur at 0.5-2 per minute. They relate to respiratory variations and Cheyne-Stokes breathing. Their clinical significance is uncertain, but they may indicate reduced compliance.

C waves have amplitude 5-10 mmHg and occur at 4-8 per minute. They relate to systemic blood pressure oscillations, known as Traube-Hering-Mayer waves, and are usually not pathological.

Examiner: This patient has ICP of 28 mmHg. How do you manage this?

Candidate: I would use a tiered approach.

For Tier 0 or optimisation, I would ensure head elevation at 30 degrees with midline position, loosen any cervical collar, ensure adequate sedation and analgesia, treat any fever or seizure activity, and confirm the ICP reading is accurate.

For Tier 1 or first-line interventions, I would drain CSF via the EVD, typically 10-20 mL. I would give osmotherapy, either mannitol 0.5-1 g/kg or 3% hypertonic saline 250 mL. I would increase sedation and ensure normocapnia with PaCO2 35-40 mmHg. I would also consider neuromuscular blockade to reduce metabolic demand.

If ICP remains elevated, for Tier 2 I would use mild hyperventilation to PaCO2 30-35 mmHg as a bridge therapy, though this should not be sustained. I would repeat CT to evaluate for surgical lesion such as hydrocephalus, haematoma, or infarct. Continuous neuromuscular blockade would be initiated if not already commenced.

For Tier 3 or rescue therapies, options include barbiturate coma with thiopental or pentobarbital titrated to EEG burst suppression, decompressive craniectomy, and moderate hypothermia to 32-35 degrees Celsius, though evidence for this in SAH is limited.

Examiner: What is CPPopt?

Candidate: CPPopt is the concept of optimal cerebral perfusion pressure, defined as the CPP at which autoregulatory capacity is maximal. This is identified using the pressure reactivity index, PRx, which correlates slow waves of MAP and ICP. The CPP at which PRx is most negative represents the best autoregulation.

Targeting individualised CPPopt rather than fixed thresholds has been associated with improved outcomes in observational studies. The COGiTATE trial provided proof-of-concept that CPPopt-guided management is feasible, and larger RCTs are underway.

In practice, CPPopt may change over time and can be displayed continuously at the bedside using ICM+ or similar software, allowing dynamic CPP targets.

Examiner: Thank you. That concludes this viva.

---

References

Landmark References

1. Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev. 1959;39(2):183-238. PMID: 13645234

2. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Clin Invest. 1948;27(4):476-483. PMID: 16695568

3. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg. 1982;57(6):769-774. PMID: 2010644

4. Lundberg N. Continuous recording and control of ventricular fluid pressure in neurosurgical practice. Acta Psychiatr Scand Suppl. 1960;36(149):1-193. PMID: 13729328

Cerebral Autoregulation

5. Brassard P, Labrecque L, Smirl JD, et al. Losing the dogmatic view of cerebral autoregulation. Physiol Rep. 2021;9(15):e14982. PMID: 34197581

6. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 1990;2(2):161-192. PMID: 2201348

7. Czosnyka M, Smielewski P, Kirkpatrick P, et al. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41(1):11-17. PMID: 9218290

8. Steiner LA, Czosnyka M, Piechnik SK, et al. Continuous monitoring of cerebrovascular pressure reactivity allows determination of optimal cerebral perfusion pressure in patients with traumatic brain injury. Crit Care Med. 2002;30(4):733-738. PMID: 11940737

9. Aries MJ, Czosnyka M, Budohoski KP, et al. Continuous determination of optimal cerebral perfusion pressure in traumatic brain injury. Crit Care Med. 2012;40(8):2456-2463. PMID: 22622366

10. Rivera-Lara L, Zorrilla-Vaca A, Geocadin RG, et al. Cerebral autoregulation-oriented therapy at the bedside: a comprehensive review. Anesthesiology. 2017;126(6):1187-1199. PMID: 28426431

Intracranial Pressure

11. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, Fourth Edition. Neurosurgery. 2017;80(1):6-15. PMID: 27654000

12. Wilson MH. Monro-Kellie 2.0: The dynamic vascular and venous pathophysiological components of intracranial pressure. J Cereb Blood Flow Metab. 2016;36(8):1338-1350. PMID: 27174995

13. Hawthorne C, Piper I. Monitoring of intracranial pressure in patients with traumatic brain injury. Front Neurol. 2014;5:121. PMID: 25071706

14. Steiner LA, Andrews PJ. Monitoring the injured brain: ICP and CBF. Br J Anaesth. 2006;97(1):26-38. PMID: 16698864

15. Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. J Neurol Neurosurg Psychiatry. 2004;75(6):813-821. PMID: 15145991

Cerebral Metabolism

16. Siesjo BK. Cerebral circulation and metabolism. J Neurosurg. 1984;60(5):883-908. PMID: 6425463

17. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981;40(8):2311-2316. PMID: 7238911

18. Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med. 1984;25(2):177-187. PMID: 6610032

19. Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature. 2010;468(7321):232-243. PMID: 21068832

20. Buxton RB. The physics of functional magnetic resonance imaging (fMRI). Rep Prog Phys. 2013;76(9):096601. PMID: 24006360

CO2 Reactivity

21. Brian JE Jr. Carbon dioxide and the cerebral circulation. Anesthesiology. 1998;88(5):1365-1386. PMID: 9605698

22. Harper AM, Glass HI. Effect of alterations in the arterial carbon dioxide tension on the blood flow through the cerebral cortex at normal and low arterial blood pressures. J Neurol Neurosurg Psychiatry. 1965;28(5):449-452. PMID: 5838296

23. Muizelaar JP, Marmarou A, Ward JD, et al. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg. 1991;75(5):731-739. PMID: 1919695

24. Coles JP, Fryer TD, Coleman MR, et al. Hyperventilation following head injury: effect on ischemic burden and cerebral oxidative metabolism. Crit Care Med. 2007;35(2):568-578. PMID: 17205021

Blood-Brain Barrier

25. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25. PMID: 19664713

26. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201. PMID: 18215617

27. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. PMID: 25561720

28. Shlosberg D, Bhattacharya M, Bhattacharya A, et al. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010;6(7):393-403. PMID: 20551947

Jugular Venous Oximetry

29. Cruz J. The first decade of continuous monitoring of jugular bulb oxyhemoglobin saturation: management strategies and clinical outcome. Crit Care Med. 1998;26(2):344-351. PMID: 9468176

30. Macmillan CS, Andrews PJ. Cerebrovenous oxygen saturation monitoring: practical considerations and clinical relevance. Intensive Care Med. 2000;26(8):1028-1036. PMID: 11030158

31. Stocchetti N, Paparella A, Bridelli F, et al. Cerebral venous oxygen saturation studied with bilateral samples in the internal jugular veins. Neurosurgery. 1994;34(1):38-43. PMID: 8121566

Temperature Effects

32. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549-556. PMID: 11856793

33. Nielsen N, Wetterslev J, Cronberg T, et al. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med. 2013;369(23):2197-2206. PMID: 24237006

34. Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283-2294. PMID: 33197436

35. Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for intracranial hypertension after traumatic brain injury. N Engl J Med. 2015;373(25):2403-2412. PMID: 26444221

Brain Tissue Oxygen

36. Okonkwo DO, Shutter LA, Moore C, et al. Brain oxygen optimization in severe traumatic brain injury phase-II: a phase II randomized trial. Crit Care Med. 2017;45(11):1907-1914. PMID: 29136083

37. Oddo M, Levine JM, Mackenzie L, et al. Brain hypoxia is associated with short-term outcome after severe traumatic brain injury independently of intracranial hypertension and low cerebral perfusion pressure. Neurosurgery. 2011;69(5):1037-1045. PMID: 21673608

38. Maloney-Wilensky E, Gracias V, Itkin A, et al. Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review. Crit Care Med. 2009;37(6):2057-2063. PMID: 19384213

Pharmacological Effects

39. Kaisti KK, Metsahonkala L, Teras M, et al. Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. Anesthesiology. 2002;96(6):1358-1370. PMID: 12170048

40. Schlunzen L, Vafaee MS, Cold GE, et al. Effects of dose-dependent levels of isoflurane on cerebral blood flow in healthy subjects studied using positron emission tomography. Acta Anaesthesiol Scand. 2006;50(3):306-312. PMID: 16480464

41. Zeiler FA, Teitelbaum J, West M, Bhalla SK. The ketamine effect on intracranial pressure in nontraumatic neurological illness. J Crit Care. 2014;29(6):1096-1106. PMID: 25086912

42. Chez MG, Koo B, Bhalla SK. Ketamine-based anesthesia and rising ICP in pediatric patients with acute encephalitis. Pediatr Neurol. 2015;52(6):e9-10. PMID: 25680659

Clinical Guidelines

43. Robertson CS, Valadka AB, Hannay HJ, et al. Prevention of secondary ischemic insults after severe head injury. Crit Care Med. 1999;27(10):2086-2095. PMID: 10548187

44. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737. PMID: 22556195

45. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418. PMID: 31662037

Australian/New Zealand Context

46. ANZICS Centre for Outcome and Resource Evaluation. Adult Patient Database (APD) Report 2021-2022. Melbourne: ANZICS CORE; 2023.

47. Anderson I, Robson B, Connolly M, et al. Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study. Lancet. 2016;388(10040):131-157. PMID: 27108232

48. Jamieson LM, Sayers SM, Roberts-Thomson KF. Clinical oral health outcomes in young Australian Aboriginal adults compared with national-level counterparts. Med J Aust. 2010;192(10):558-561. PMID: 20477729

---

Summary Table

---

Related Topics

• Traumatic Brain Injury
• Intracranial Hypertension
• Subarachnoid Haemorrhage
• Neurophysiology
• Cardiovascular Physiology
• Temperature Regulation